Medical Marijuana Inc (OTCMKTS:MJNA) Appreciates WHO’s ECDD For Keeping Focus On Cannabis In Its 40th Annual Meeting


Medical Marijuana Inc (OTCMKTS:MJNA) has appreciated the initiative by the United Nations World Health Organization’s Expert Committee on Drug Dependence (ECDD) to focus on reviewing cannabis and marijuana-related substances in its 40th Annual Meeting. The first American publicly traded cannabis company also recently took part in the 5th Annual Cannabis World Congress and Business Expo (CWCBE) held from May 31 and June 2 in the New York City.

MJNA Expects To Continue As Leader

According to reports, the Chief Executive Officer, Dr. Stuart Titus spoke on medical cannabis and cannabidiol (CBD) research on May 31. The company’s subsidiary, HempMeds is expected to exhibit its retail-ready cannabis products and also its line of CBD hemp oil products. Prior to the expo, the CEO of the company said, “I am looking forward to the opportunity to spread education on cannabis and specifically CBD so that we can begin to clear up some misconceptions and further cannabis research.”

He added that since the Real Scientific Hemp Oil (RSHO) has received its first-ever import permit from the countries of Brazil, Mexico, and Paraguay, it is a clear indication that the global market for the products of hemp cannabidiol (CBD) is expanding. He also stated that MJNA wants to continue being the leader in this industry.

Titus Expects WHO To Eliminate CBD From Drug Category

The CEO of MJNA recently also said that the company is very much excited for World Health Organization and United Nations as they made final recommendations regarding the CBD products after certain findings revealed the significance of these products. The details were released in November 2017 during the 39th ECDD meeting where the HempMeds President Latin America, Raul Elizalde spoke about how his daughter managed to become seizure-free due to the therapeutic benefits of CBD.

According to Titus, although the initial evidence from both animal and human studies establishes that CBD has some therapeutic benefits, the company is positive that after these findings WHO will surely eliminate CBD from the list of a scheduled drug. He further added that if WHO agrees to the selling of CBD as a nutritional supplement, it will open up a big market and new opportunities and the products could be sold in so many health and wellness retail locations around the world.


About Author

Leave A Reply